Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Pyrosequencing and University of Geneva Add To Down Syndrome Diagnostics Deal

NEW YORK, May 7-The Swedish firm Pyrosequencing and the University of Geneva today said that they would work together to develop new prenatal screens for a range of chromosomal diseases.


The research project expands upon a collaboration launched last August to develop a diagnostic for Down Syndrome. The test has been created and is now being clinically evaluated.


This expanded partnership will develop genetic tests for other types of chromosomal trisomy, including trisomy 18 (Edward's Syndrome) and trisomy 13 (Patau's Syndrome). These syndromes, while less common than Down syndrome, cause profound mental retardation and generally fatal health problems.


The collaboration is structured so that Pyrosequencing's Molecular Diagnostics business unit sponsors research at the Swiss university to carry out the gene analysis. Financial details were not revealed.


Pyrosequencing is a publicly held company based in Uppsala, Sweden.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.